Addimmune™ CEO Jeff Galvin joins ShareTreck host Raj Natarajan in this compelling interview to discuss the company’s launch as well as updates on AGT103-T, Addimmune’s HIV therapeutic. Following a successful Phase 1 clinical trial, will build AGT’s success, accelerating the clinical development with dedicated investment and singular focus on HIV.
